Veralto: Videojet Pharma Coding Solutions
Former Pharma director at Videojet
inpractise.com/articles/veralto-videojet-pharma-tco-and-aftermarket
Former Pharma director at Videojet
Interview Transcript
This is a snippet of the transcript, sign up to read more.
And you mean each person on the manufacturing line, correct?
Yes, exactly. Not only the operators responsible for the printer, but also each time you have to change something in the printer's parameters, or if you want to change a cartridge or ink, you have to record everything. This is a requirement from the pharma market specifically for US. However, now it's global. You have specific software, and when you install any kind of printer, you must provide specific documentation.
This is a snippet of the transcript, sign up to read more.
So you mean the OEMs are the companies that sell the actual assembly line?
Yes, that's correct. It was about 50/50 because when I left, Videojet serialization was still at its peak, which is not the case anymore. There are fewer serialization projects now. I suppose the split is probably 70% on the end user and a maximum of 30% on the OEMs for pharma.
This is a snippet of the transcript, sign up to read more.
What's the typical cost of the equipment a customer would pay for? Let's think about one assembly line.
The printing cost is minimal compared to the cost of an assembly line. For a complete assembly line, we're talking about millions. How much? Around 2 or 2.5 million. The printers cost a maximum of €5,000 each.
This is a snippet of the transcript, sign up to read more.
Related Content
Danaher's Culture, Pall Industrial, & Deploying DBS
Former VP at Danaher
Danaher Business System: PSP, Kaizen, & Six Sigma
Former Director at Danaher
Danaher: DBS Office Operational Strategy
Former Director at Danaher DBS Office
Danaher: DBS Office Structure & Policy Deployment
Former Global DBS Director at Danaher
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.